Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI)

D. Bell (Belfast , United Kingdom), W. Timmer (Gauting, Germany), L. Mansfield (Cambridge, United Kingdom), M. Lomax (Cambridge, United Kingdom), B. Grothe (Cambridge, United Kingdom), T. Overend (Cambridge, United Kingdom)

Source: International Congress 2018 – Innovative therapies in asthma and COPD
Session: Innovative therapies in asthma and COPD
Session type: Poster Discussion
Number: 610
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Bell (Belfast , United Kingdom), W. Timmer (Gauting, Germany), L. Mansfield (Cambridge, United Kingdom), M. Lomax (Cambridge, United Kingdom), B. Grothe (Cambridge, United Kingdom), T. Overend (Cambridge, United Kingdom). Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI). 610

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: